Full-Time

Senior Software Engineer

Invert

Invert

11-50 employees

Biomanufacturing technology to produce materials

No salary listed

Remote in USA + 1 more

More locations: Remote in Canada

Remote

Category
Software Engineering (1)
Required Skills
FastAPI
Python
Kinesis
Postgres
TypeScript
AWS
Terraform
Next.js
Requirements
  • Proficiency in backend development with Python, FastAPI, PostgreSQL.
  • Proficiency in frontend development with Next.js, TypeScript, Tailwind.
  • Experience with infrastructure using Terraform and Amazon Web Services.
  • Experience with artificial intelligence tooling such as Bedrock, Modal, and LiteLLM.
  • Experience with streaming data technologies such as Kinesis and Greengrass.
  • Senior role expectations include delivering through hands-on development as well as project leadership.
  • Deep backend and system design instincts; experience building at scale; good judgment on code quality.
Responsibilities
  • Ship new features and maintain existing ones.
  • Push our technical excellence and product quality.
  • Deliver through hands-on delivery and project leadership as a senior engineer.

InvertBio uses biology to produce materials and chemicals for industries that rely on physical inputs, offering biomanufacturing methods that enable greener, scalable production. Biological systems perform the making through bioprocesses like fermentation and enzyme pathways, turning living organisms into practical inputs produced more sustainably. Unlike traditional manufacturing, it emphasizes sustainable, scalable bio-based production to cut environmental impact and costs for manufacturing, agriculture, and pharmaceuticals. Its goal is to help industries transition to greener, cost-effective production by supplying biology-based materials and services that meet growing demand.

Company Size

11-50

Company Stage

Early VC

Total Funding

$20.3M

Headquarters

San Francisco, California

Founded

2021

Simplify Jobs

Simplify's Take

What believers are saying

  • Raised $20.1M in 2026 to expand product development aggressively.
  • Expanding from synthetic biology into mission-critical biopharma data management.
  • Customers save time comparing results across scales and sharing insights organization-wide.

What critics are saying

  • Synthace steals market share in fermentation scaling within 6-12 months.
  • Invert Assist hallucinations fail FDA validation in biopharma within 3-6 months.
  • Post-funding dilution forces 10x growth, causing bugs and churn in 6-12 months.

What makes Invert unique

  • Invert Assist outperforms ChatGPT by over twice in bioprocess optimization benchmarks.
  • Platform automates data unification from lab to production without code.
  • Provides full traceability with executable Python code for regulated environments.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Unlimited Paid Time Off

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

9%

2 year growth

17%
intelligence360
Jul 24th, 2024
Invert Has Filed A Notice Of An Exempt Offering Of Securities To Raise $20,100,000.00 In New Equity Investment.

Invert has filed a notice of an exempt offering of securities to raise $20,100,000.00 in New Equity Investment. Invert has filed a notice of an exempt offering of securities to raise $20,100,000.00 in New Equity Investment.According to filings with the U.S. Securities and Exchange Commission, Invert is raising up to $20,100,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Martin Permin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.About InvertInvert builds software for bioprocessing. With Invert, your team has full transparency into all your bioprocess data from lab to production, including full process traceability from upstream to formulation. Your team will save time juggling manual data, get to insights faster, and collaborate seamlessly across teams and partners

Securities and Exchange Commission
Jul 13th, 2024
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

Forbes
Jul 24th, 2023
There Is No Problem Biology Can'T Solve…Except For Economics

Reptile8488 (Canva)Do you remember when the first fully electric vehicles came out in the early 2000s, and we all said, "Neat, but where are you going to plug it in?" Now—pause for emphasis—a full two decades later—electric vehicles are starting to become commonplace, but they still only account for about 1% of US auto sales.Electricity is cool, as long as it doesn't come from burning coal, but what if our fuel sources could be not only carbon neutral but actually carbon negative? That is the promise of biology.Yeast, bacteria, plants, and algae can use a huge variety of fuel sources—sugar, organic waste, and even greenhouse gases – to produce molecules that we can use for fuel, medicine, plastics, building materials, clothing, cosmetics, and more."It requires a bunch of tinkering and some cell engineering. But you can get [microorganisms] to consume basically anything and make basically anything," said Joshua Lachter, Co-Founder of Synonym Bio, a financing and development platform for biomanufacturing. "That's the idea, the hope, and the dream.". SynBioBetaSynthetic biologists at universities and companies around the world have shown that we can use biomanufacturing to produce hundreds of materials that are currently unsustainably sourced. So, what's the hold-up?For electric vehicles to become more ubiquitous, two shifts have occurred: One in economics, fuel prices went up, and the cost of manufacturing electric vehicles went down; One in infrastructure, EV charging stations popped up everywhere from condos to coffee shops.In order for biomanufacturing to reach its full potential, we have to build an infrastructure, and it's got to be cheap